|
Post by afrezzamiracle on Feb 28, 2018 1:35:09 GMT -5
I’m blown away after listening to Dr. Kendall speak. Mike Castagna has assembled a tremendous team and we will be executing on his vision successfully for MANY years to come. Great call today! The future is bright fellow longs!
|
|
|
Post by celo on Feb 28, 2018 2:07:07 GMT -5
The weight and strength Dave will carry around to endocrinologist at the ADA and in publications is immense. He is ready to answer any question about the STAT study and put to work the data from 60 other previous studies. This guy can make doctors head spin if they question him.
|
|
|
Post by akemp3000 on Feb 28, 2018 2:50:06 GMT -5
And...Kudos to Mike Castagna for enticing Dr. Kendall to come aboard. Mike C has completely reorganized and refocused this company in less than a year as CEO. IMO both men will one day be globally recognized for their contributions to the industry.
|
|
|
Post by kc on Mar 1, 2018 12:21:30 GMT -5
|
|
|
Post by therealisaching on Mar 1, 2018 12:48:59 GMT -5
Dynamite interview. It's been so frustrating to see the slow uptake in Afrezza use. We all see how this is the best meal time insulin. Its really sunk in for me over the last year that what is so difficult about the change is that this is a paradigm shift. We can argue all we want about pricing, etc. Think about how our medical system works. If you see your primary care doc its only for 15 minutes. They are pressed for time. They know a certain insulin regimen that has "worked" for their patients. We live in a litigious society. Liability insurance is a real world concern for practitioners. Why make the change? What's the compelling reason? Without knowledge there hasn't been one. Happy to keep doing what I'm doing because I'm doing no harm.
Then those who initially gave it a try under Sanofi were given boxes with no explanation that it isn't a dose for dose medication. Patients didn't renew. So again how to convince a practitioner to adopt Afrezza?
Dr. Kendall sees the opportunity and is the 2nd lightning strike for the company (Mike being the first). Mike alluded to all of the research that has been done at the Noblecon presentation. Dr Kendall sees it too and is going to be very credible getting this information out into the medical community.
MNKD has come a long way since getting the product back. What a great hire.
|
|
|
Post by uvula on Mar 1, 2018 14:35:49 GMT -5
I LOVE his quote " I see the lung as our tool, not as a potential danger."
|
|
|
Post by dreamboatcruise on Mar 1, 2018 14:51:43 GMT -5
That was a good interview. I am curious about the very last paragraph. "I absolutely see a need to bring that language into the conversation at MannKind, in talking to healthcare providers and working with our regulatory team, advocates and others. We'd love to include patient stories and examples in product information, and in what we share with healthcare providers." Is there really any chance they can put patient stories and examples (anecdotal clinical data?) in product information? Is this a realistic goal, or is it more like saying "We'd love to have world peace and the end of poverty".
|
|
|
Post by celo on Mar 1, 2018 15:27:48 GMT -5
That was a good interview. I am curious about the very last paragraph. "I absolutely see a need to bring that language into the conversation at MannKind, in talking to healthcare providers and working with our regulatory team, advocates and others. We'd love to include patient stories and examples in product information, and in what we share with healthcare providers." Is there really any chance they can put patient stories and examples (anecdotal clinical data?) in product information? Is this a realistic goal, or is it more like saying "We'd love to have world peace and the end of poverty". This paragraph that precedes your paragraph describes a dream he had. I believe, it's a continuation of his dream. "My dream is to have an FDA leader who personally lives with type 1 and understands what it’s like to have a blood glucose of 220 versus 110, what it feels like to have an hour’s worth of glucose values in the 50s, how it disrupts your day. All of that isn’t captured in A1C or necessarily in (regular meter monitoring), and recovery from a significant low can take more than an hour out of your day. Those things go into the value, and it’s what we can show being addressed with Afrezza, using technology to show that." Probably just saying bundle up patients stories like the authors and find the data that backs them up. Then put that data's conclusions in product information.
|
|
|
Post by bill on Mar 1, 2018 19:47:26 GMT -5
Since we're not employed or encumbered by FDA regulations, might it make sense for this board's activists to create our own professionally created Afrezza web site that displays all the best information we've reviewed. Once we have it we could then pay the fees to ensure it's prominently displayed in Google (and Bing) search results. I'd be willing to contribute some funding and even help a bit--IT stuff not web design things...
Thoughts?
|
|
|
Post by robbmo on Mar 1, 2018 20:21:32 GMT -5
I LOVE his quote " I see the lung as our tool, not as a potential danger." I am quite fond of this one: :-) "I remember the launches of Humalog (in 1996) and having individuals come back to me and say, “I don’t know what you’ve done, but I want a refill on that insulin because it changed my meal-time experience.” I think Afrezza can do the same in a way we haven’t seen since then."
|
|
|
Post by sayhey24 on Mar 1, 2018 20:48:06 GMT -5
That was a good interview. I am curious about the very last paragraph. "I absolutely see a need to bring that language into the conversation at MannKind, in talking to healthcare providers and working with our regulatory team, advocates and others. We'd love to include patient stories and examples in product information, and in what we share with healthcare providers." Is there really any chance they can put patient stories and examples (anecdotal clinical data?) in product information? Is this a realistic goal, or is it more like saying "We'd love to have world peace and the end of poverty". DBC - the question Dr. Kendall is addressing is "Has MannKind embraced the “Beyond A1C” message for Afrezza?" The short answer is no, they have not. Mike and guys main focus has been A1c. Are they aware of it sure but its not what they have been about. We here on Proboards have been focused on “Beyond A1C” for a very long time. We have been talking about time in range, use of the CGM, Cloud Monitoring and the Libre way before it was approved. We have known afrezza is a real time solution to a real time problem which is "Stopping the Spike" after meals. Mike and team's main focus has been A1c and not TIR. What we do know is Dr. Kendall has found the treasurer chest filled with the 60+ studies. Can he combine these studies in conjunction with non-scientifc data which shows an example like the VDex whitepaper, maybe? The thing about the VDex paper is its a do it yourself instruction kit - if you don't believe their paper try it yourself. Lets see what he can come up with.
|
|
|
Post by straightly on Mar 1, 2018 21:17:31 GMT -5
Since we're not employed or encumbered by FDA regulations, might it make sense for this board's activists to create our own professionally created Afrezza web site that displays all the best information we've reviewed. Once we have it we could then pay the fees to ensure it's prominently displayed in Google (and Bing) search results. I'd be willing to contribute some funding and even help a bit--IT stuff not web design things... Thoughts? Second.
|
|
|
Post by straightly on Mar 1, 2018 21:29:34 GMT -5
That was a good interview. I am curious about the very last paragraph. "I absolutely see a need to bring that language into the conversation at MannKind, in talking to healthcare providers and working with our regulatory team, advocates and others. We'd love to include patient stories and examples in product information, and in what we share with healthcare providers." Is there really any chance they can put patient stories and examples (anecdotal clinical data?) in product information? Is this a realistic goal, or is it more like saying "We'd love to have world peace and the end of poverty". DBC - the question Dr. Kendall is addressing is "Has MannKind embraced the “Beyond A1C” message for Afrezza?" The short answer is no, they have not. Mike and guys main focus has been A1c. Are they aware of it sure but its not what they have been about. We here on Proboards have been focused on “Beyond A1C” for a very long time. We have been talking about time in range, use of the CGM, Cloud Monitoring and the Libre way before it was approved. We have known afrezza is a real time solution to a real time problem which is "Stopping the Spike" after meals. Mike and team's main focus has been A1c and not TIR. What we do know is Dr. Kendall has found the treasurer chest filled with the 60+ studies. Can he combine these studies in conjunction with non-scientifc data which shows an example like the VDex whitepaper, maybe? The thing about the VDex paper is its a do it yourself instruction kit - if you don't believe their paper try it yourself. Lets see what he can come up with. WOW! I am very much impressed. Mike hit the titration issue. Now Dr. Kendall is hitting the "Beyond A1C", even though saying "Mike and guys main focus has been A1C" is not fair: I vividly remember Mike got REALLY excited when Libre was approved. Somebody on this board even questioned why Mike was so excited and even "advertising" for Libre. But "Beyond A1C" is absolutely the knocker! Now let's hear some noises!
|
|
|
Post by olebob1 on Mar 1, 2018 22:36:08 GMT -5
Since we're not employed or encumbered by FDA regulations, might it make sense for this board's activists to create our own professionally created Afrezza web site that displays all the best information we've reviewed. Once we have it we could then pay the fees to ensure it's prominently displayed in Google (and Bing) search results. I'd be willing to contribute some funding and even help a bit--IT stuff not web design things... Thoughts? Second straightly: Do you mean Second that emotion or On Second Thought?
|
|
|
Post by straightly on Mar 1, 2018 23:41:39 GMT -5
straightly: Do you mean Second that emotion or On Second Thought? Second that motion. There was a suggestion here earlier that, if every stock holder can get one diabetes to get Afrezza, our prescription count will be much higher. This is in the same line.
|
|